---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-035365"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2024-03-22T23:59:59+00:00"
generated_at: "2026-06-04T09:26:44.029921+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics enters new ATM facility with B. Riley; FDA delays OPC1 study start

## Summary
- Entered Sales Agreement with B. Riley Securities to sell up to $6.7M in common shares via at-the-market offering; 3% commission.
- Terminated prior ATM with Cantor Fitzgerald; prior program sold approximately $6.66M in shares.
- FDA review of OPC1 IND for spinal cord injury ongoing; requested not to initiate DOSED study until feedback expected by April 26, 2024.
- Initial FDA clinical information request resolved; company aims to open first DOSED study site in Q2 2024.
- No change to previously guided timeline for study initiation; no additional activities required to address FDA request.

## SEC filing metadata
- accession: 0000950170-24-035365
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2024-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000095017024035365/0000950170-24-035365-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000095017024035365/lctx-20240312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-035365
- JSON: https://secwatch.observer/filing/0000950170-24-035365.json
- Plain text: https://secwatch.observer/filing/0000950170-24-035365.txt

## Key facts
- Material Agreements
  Lineage Cell Therapeutics, Inc. entered into Sales Agreement with B. Riley Securities, Inc. (effective 2024-03-22).
  - Action: entry
  - Agreement: atm program
  - Counterparty: B. Riley Securities, Inc.
  - Effective: 2024-03-22
  source text: on March 22, 2024, Lineage Cell Therapeutics, Inc. (the “Company” or “Lineage”), entered into a sales agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (the “Sales Agent”), under which the Company may offer and sell its common shares from time to time through the Sales Agent as the Company’s sales agent.
  evidence_url: https://www.sec.gov/Archives/edgar/data/876343/000095017024035365/0000950170-24-035365-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.